Quest Diagnostics Incorporated (DGX)
Healthcare · NYQ · US
Price as at 1 Oct 2026, 02:41 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Quest Diagnostics Incorporated trades at $233.07, which is 25% below the $292.02 our fair value estimate puts on the business. On that measure alone it screens as undervalued, though a valuation model is an argument rather than a measurement, and the market is frequently right about why something is cheap.
Our moat model scores it 52 out of 100, which is a moat, but not a deep one. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
It changes hands at 24.6 times earnings. Be careful reading that in isolation: for a cyclical business a low P/E arrives at the top of the cycle, when profits are peaking and about to fall, which is exactly when the shares look cheapest and are not.
DGX dividend history
Dividends per share by year
| Year | Total per share | Payments |
|---|---|---|
| 2026 (year to date) | $2.52 | 3 |
| 2025 | $3.15 | 4 |
| 2024 | $2.96 | 4 |
| 2023 | $2.79 | 4 |
| 2022 | $2.60 | 4 |
| 2021 | $2.42 | 4 |
| 2020 | $2.21 | 4 |
| 2019 | $2.12 | 4 |
| 2018 | $1.95 | 4 |
| 2017 | $1.80 | 4 |
| 2016 | $1.58 | 4 |
Split-adjusted amounts in the listing currency, grouped by the calendar year of the ex-dividend date, from the filed record. Growth and streak figures compare complete years only.
DGX earnings and analyst estimates
Recommendation mix, 17 published ratings
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About Quest Diagnostics Incorporated
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
DGX passes 3 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Super investor ownership
12 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Jeremy Grantham, Grantham, Mayo, Van Otterloo & Co. LLC$400.21M · 0.9% of book
- Christopher Davis, DAVIS SELECTED ADVISERS$329.78M · 1.4% of book
- Marshall Wace, MARSHALL WACE, LLP$57.18M · 0.1% of book
- Ken Griffin, CITADEL ADVISORS LLC$28.23M · 0.0% of book
- Joel Greenblatt, Gotham Asset Management, LLC$24.91M · 0.1% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Politician trades in DGX
We hold 21 disclosed trades in DGX by members of Congress and executive-branch officials. The latest 5:
- Donald J Trump · Executive branchSell · $15,001 - $50,000 · traded 23 Jul 2026 · disclosed 22 Sept 2026
- Donald J Trump · Executive branchSell · $1,001 - $15,000 · traded 12 Jun 2026 · disclosed 22 Aug 2026
- Donald J Trump · Executive branchBuy · $100,001 - $250,000 · traded 18 May 2026 · disclosed 1 Jul 2026
- Donald J Trump · Executive branchBuy · $100,001 - $250,000 · traded 11 May 2026 · disclosed 1 Jul 2026
- Alan Armstrong · SenateBuy · $1,001 - $15,000 · traded 30 Mar 2026 · disclosed 21 Jul 2026
A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.
DGX peers
The largest companies in the same industry (Diagnostics & Research), then in the same sector.
- TMO Thermo Fisher Scientific Inc.
- WAT Waters Corporation
- ICLR ICON Public Limited Company
- CRL Charles River Laboratories International, Inc.
- QIA.DE Qiagen N.V.
- BLLN BillionToOne, Inc.
- SHC Sotera Health Company
- ADPT Adaptive Biotechnologies Corporation
Every healthcare company we cover is on the Healthcare hub.
Common questions
Is Quest Diagnostics Incorporated (DGX) undervalued?
Against our fair value estimate of $292.02, DGX at $233.07 is 25% below fair value. That is one model's answer, not a recommendation. It is built from normalized earning power with growth capped deliberately low, which understates companies whose value is mostly future growth.
Which funds own DGX?
12 of the institutions we track reported a position in DGX in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
What is DGX's P/E ratio?
DGX trades at 24.6 times earnings. A low P/E is not automatically cheap: on a cyclical company it is usually a warning that earnings are at a peak.
Does Quest Diagnostics Incorporated (DGX) pay a dividend?
Yes. Quest Diagnostics Incorporated yields 1.48% at the current share price. It has paid $3.32 per share over the trailing twelve months. It has paid a dividend in each of the last 22 complete calendar years. A dividend is declared by the board and can be cut at any time; a yield is a fact about the current price, not a promise.
When does DGX report earnings next?
Quest Diagnostics Incorporated is scheduled to report on 22 Oct 2026. Companies move earnings dates, so read it as scheduled rather than certain.
Where does SteadyShares get its DGX data?
Fundamentals for DGX come from company filings and exchange data, as listed on NYQ; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 02:41 UTC and is delayed. Our data quality score for this company is 100/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for DGX, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.